Ask AI
ProCE Banner Activity

CE / CME

Managing HER2 and TROP2 ADC Adverse Events: Advanced Practice Providers Case Discussions Highlighting the Critical Roles in Patient Care

Video

In this certified on-demand webcast, experts discuss the structure and mechanism of TROP-2– and HER2-directed ADCs currently used to manage both breast and lung cancers as well as recent trial updates. Faculty also cover practical treatment algorithms, case-based toxicity recognition and management, and the evolving role of biomarker testing to guide therapy selection.

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Released: December 18, 2025

Expiration: June 17, 2026

Share

Provided by

Provided by Partners for Advancing Clinical Education (Partners) in partnership with Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Partners

Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Target Audience

This activity is intended for nurse practitioners, physician associates, nurses, and other healthcare professionals who care for patients with solid tumors.

Program Learning Goal

This activity aims to improve nurses' knowledge and competence in identifying and managing TRAEs associated with antibody-drug conjugate therapies in solid tumors.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Summarize the mechanisms of action, therapeutic targets, and clinical trial data supporting the use of ADCs in treating solid tumors to guide patient-specific treatment decisions​

  • Implement proactive monitoring and evidence-based protocols for managing ADC-related TRAEs, including early identification and appropriate intervention strategies for high-risk adverse events​

  • Design patient-centered education and interprofessional communication plans that promote timely ADC-related TRAEs recognition and encourage urgency in reporting symptoms

Disclosure

Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partner policies. Others involved in the planning of this activity have no relevant financial relationships.

Primary Author

Julia LaBarbera, MSN, RN, AGACNP-BC: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo.

Beth Sandy, MSN, CRNP, FAPO: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, Catalyst, Janssen, Jazz, Lilly, Merck, Pfizer.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 18, 2025, through June 17, 2026:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Learners have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (Partners) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour, including 1 hour of pharmacotherapy credit.

Physician Associate Continuing Medical Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until June 17, 2026. PAs should only claim credit commensurate with the extent of their participation. 

IPCE Credit Designation

 

This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change.